TABLE 4.
Proportion placebo group | Proportion vitamin D group | OR (95% CI) | P value | |
---|---|---|---|---|
Participants with ≥1 exacerbation | ||||
Intention-to-treat (n = 155) | 50 of 81 (62%) | 52 of 74 (70%) | 1.55 (0.75, 3.17) | 0.23 |
Subgroup ≤25 nmol/L (n = 31) | 10 of 16 (63%) | 11 of 15 (73%) | 0.64 (0.05, 7.87) | 0.73 |
Participants with ≥1 episode of antibiotic use | ||||
Intention-to-treat (n = 155) | 43 of 81 (53%) | 44 of 74 (59%) | 1.27 (0.64, 2.50) | 0.49 |
Subgroup ≤25 nmol/L (n = 31) | 7 of 16 (44%) | 9 of 15 (60%) | 0.38 (0.02, 6.21) | 0.50 |
Participants with ≥1 episode of oral corticosteroid use | ||||
Intention-to-treat (n = 155) | 41 of 81 (51%) | 43 of 74 (58%) | 1.30 (0.66, 2.60) | 0.45 |
Subgroup ≤25 nmol/L (n = 31) | 7 of 16 (44%) | 10 of 15 (67%) | 2.57 (0.60, 11.06) | 0.20 |
1Results are based on logistic regression analyses. All analyses were adjusted for stratification group and study center. OR, odds ratio; CI, confidence interval